VFO
UTHR icon

Virtus Family Office’s United Therapeutics UTHR Stock Holding History

Virtus Family Office’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.82M Sell
3,366
-19
-0.6% -$10.7K 1.44% 27
2026
Q1 		$2.01M Sell
3,385
-323
-9% -$161K 1.71% 15
2025
Q4 		$1.81M Sell
3,708
-43
-1% -$20K 1.56% 23
2025
Q3 		$1.57M Sell
3,751
-289
-7% -$97.2K 1.47% 27
2025
Q2 		$1.16M Buy
+4,040
New +$1.21M 1.49% 30

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Virtus Family Office's UTHR Position: Q2 2026 in Review

Virtus Family Office reduced its United Therapeutics (UTHR) stake by 0.56% in Q2 2026, selling an estimated $10.7K and leaving 3,366 shares worth $1.82M. The position accounts for 1.44% of the portfolio, ranked #27.

Virtus Family Office first reported a position in UTHR in Q2 2025 and has held it in 5 quarters since. The position peaked at $2.01M in Q1 2026. 881 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Virtus Family Office held 3,366 shares of United Therapeutics worth $1.82M as of Q2 2026.
  • Virtus Family Office sold 19 United Therapeutics shares in Q2 2026, an estimated $10.7K.
  • United Therapeutics made up 1.44% of Virtus Family Office's portfolio in Q2 2026, its #27 holding.
  • Virtus Family Office first reported a position in United Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Virtus Family Office's United Therapeutics position peaked at $2.01M in Q1 2026.
  • 881 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Virtus Family Office's 13F filing for Q2 2026, filed 4 Aug 2026.